We examined the endothelin (ET) receptors mediating contractions to'/> Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat
【2h】

Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat

机译:内皮素受体介导大鼠和人肺耐药性动脉收缩:慢性缺氧对大鼠的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">We examined the endothelin (ET) receptors mediating contractions to ET-1, ET-3 and sarafotoxin S6c (SX6c) in rat pulmonary resistance arteries by use of peptide and non-peptide ET receptor antagonists. Changes induced by pulmonary hypertension were examined in the chronically hypoxic rat. The effect of the mixed ETA/ETB receptor antagonist SB 209670 on endothelin-mediated contraction was also examined in human pulmonary resistance arteries.In rat vessels, the order of potency for the endothelin agonists was SX6c=ET-3>ET-1 (pEC50 values in control rats: 9.12±0.10, 8.76±0.14 and 8.12±0.04, respectively). Maximum contractions induced by ET-3 and ET-1 were increased in vessels from chronically hypoxic rats.The ETA receptor antagonist FR 139317 (1 μM) had no effect on the potency of ET-1 in any vessel studied but abolished the increased response to ET-1 in the chronically hypoxic vessels. The ETA receptor antagonist BMS 182874 (1 μM) increased the potency of ET-1 in control rat vessels without effecting potency in the pulmonary hypertensive rat vessels.Bosentan (non-peptide mixed ETA/ETB receptor antagonist) increased the potency of ET-1 in control rat vessels but was without effect in the pulmonary hypertensive rat vessels. Bosentan (1 μM) inhibited responses to SX6c in control and chronically hypoxic rat vessels with pKb values of 5.84 and 6.11, respectively. The ETB receptor antagonist BQ-788 (1 μM) did not inhibit responses to ET-1 in any vessel tested but did inhibit responses to both SX6c and ET-3 (pKb values in control and chronically hypoxic rat vessels respectively: SX6c 7.15 and 7.22; ET-3: 6.68 and 6.89). BQ-788 (1 μM) added with BMS 182874 (10 μM) did not inhibit responses to ET-1 in control vessels but caused a significant inhibition of responses to ET-1 in chronically hypoxic preparations.SB 209670 inhibited responses to ET-1 in both control and chronically hypoxic vessels with pKb values of 7.36 and 7.39, respectively. SB 209670 (0.1 and 1 μM) virtually abolished responses to ET-1 in the human pulmonary resistance artery.In conclusion, in rat pulmonary resistance arteries, vasoconstrictions induced by ET-1, SX6c and ET-3 are mediated predominantly by activation of an ETB–like receptor. However, lack of effect of some antagonists on ET-1 induced vasoconstriction suggests that ET-1 stimulates an atypical ETB receptor. The increase in potency of ET-1 in the presence of some antagonists suggests the presence of an inhibitory ETA-like receptor. The influence of this is reduced, or absent, in the chronically hypoxic rats. Increased responses to ET-1 are observed in the chronically hypoxic rat and may be mediated by increased activation of ETA receptors. SB 209670 is unique in its potency against responses to ET-1 in both control and chronically hypoxic rats, as well as human, isolated pulmonary resistance arteries.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 我们通过使用肽和非肽ET受体拮抗剂研究了介导大鼠肺阻力动脉中ET-1,ET-3和sarafotoxin S6c(SX6c)收缩的内皮素(ET)受体。在慢性低氧大鼠中检查了由肺动脉高压引起的变化。还检测了ETA / ETB受体拮抗剂SB 209670的混合在人肺阻力动脉中对内皮素介导的收缩的作用。 在大鼠血管中,内皮素激动剂的效价顺序为SX6c = ET- 3> ET-1(对照大鼠中的pEC50值:分别为9.12±0.10、8.76±0.14和8.12±0.04)。慢性低氧大鼠的血管中ET-3和ET-1引起的最大收缩增加。 ETA受体拮抗剂FR 139317(1μM)对任何血管中ET-1的效力均无影响研究了但消除了慢性低氧血管对ET-1的反应增加。 ETA受体拮抗剂BMS 182874(1μM)增加了ET-1在对照大鼠血管中的效力,而不影响肺动脉高压大鼠血管中的效力。 波生坦(非肽ETA / ETB混合受体拮抗剂)增加了ET-1在对照大鼠血管中的效力,但对肺动脉高压大鼠血管没有作用。波生坦(1μm)在对照和慢性低氧大鼠血管中抑制对SX6c的反应,其pKb值分别为5.84和6.11。 ETB受体拮抗剂BQ-788(1μm)在任何测试的血管中均未抑制对ET-1的反应,但同时抑制了对SX6c和ET-3的反应(对照和慢性低氧大鼠血管中的pKb值:SX6c 7.15和7.22 ; ET-3:6.68和6.89)。 BQ-788(1μm)和BMS 182874(10μm)并没有抑制对照组低氧制剂对ET-1的反应,但是对慢性低氧制剂的ET-1产生了明显的抑制作用。 SB 209670在对照和慢性低氧血管中均抑制了ET-1的反应,pKb值分别为7.36和7.39。 SB 209670(0.1和1μm)实际上消除了人肺阻力动脉中对ET-1的反应。 总而言之,在大鼠肺阻力动脉中,ET-1,SX6c和ET-3诱导的血管收缩主要通过激活ETB样受体介导。但是,某些拮抗剂对ET-1诱导的血管收缩作用的缺乏表明ET-1刺激了非典型的ETB受体。在某些拮抗剂的存在下,ET-1的效力增加表明存在抑制性的ETA样受体。在慢性低氧大鼠中,这种影响的减少或消失。在慢性低氧大鼠中观察到对ET-1的反应增加,并且可能由ETA受体的活化增加介导。 SB 209670在对照和慢性低氧大鼠以及人类分离的肺部阻力动脉中对ET-1的反应具有独特的效力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号